Negative regulation-resistant p53 variant enhances oncolytic adenoviral gene therapy

Human Gene Therapy

Volumn 23, Issue 6, 2012, Pages 609-622

  Koo, Taeyoung ^a   Choi, Il Kyu ^b   Kim, Minjung ^a   Lee, Jung Sun ^a   Oh, Eonju ^a   Kim, Jungho ^c   Yun, Chae Ok ^d  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Sogang University   (South Korea)

^d Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; GENOMIC DNA; ONCOLYTIC ADENOVIRUS; PROTEIN BAX; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PROTEIN VP16;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN CANCER; CANCER CELL CULTURE; CANCER GENE THERAPY; CARBOXY TERMINAL SEQUENCE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DNA DEGRADATION; DRUG CYTOTOXICITY; GENE DELETION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WILD TYPE;

ADENOVIRIDAE; ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; DOWN-REGULATION; GENETIC THERAPY; GENETIC VARIATION; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, NUDE; MICROSCOPY, ELECTRON, TRANSMISSION; NEOPLASMS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

ADENOVIRIDAE; MUS; SIMPLEXVIRUS;

EID: 84864365426     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.114     Document Type: Article

References (45)

1. Barak, Y., Juven, T., Haffner, R., and Oren, M. (1993). mdm2 expression is induced by wild type p53 activity. EMBO J. 12, 461-468. (Pubitemid 23073692)
2. Chene, P. (2003). Inhibiting the p53-MDM2 interaction: An important target for cancer therapy. Nat. Rev. Cancer 3, 102-109. (Pubitemid 37328877)
3. Choi, K.J., Kim, J.H., Lee, Y.S., et al. (2006). Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther. 13, 1010-1020.
4. de Belle, I., Huang, R.P., Fan, Y., et al. (1999). p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis. Oncogene 18, 3633-3642. (Pubitemid 29322388)
5. Donehower, L.A., and Bradley, A. (1993). The tumor suppressor p53. Biochim. Biophys. Acta 1155, 181-205. (Pubitemid 23246695)
6. el-Deiry, W.S. (1998). Regulation of p53 downstream genes. Semin. Cancer Biol. 8, 345-357. (Pubitemid 29131356)
7. Fakharzadeh, S.S., Rosenblum-Vos, L., Murphy, M., et al. (1993). Structure and organization of amplified DNA on double minutes containing the mdm2 oncogene. Genomics 15, 283-290. (Pubitemid 23099792)
8. Freedman, D.A., Wu, L., and Levine, A.J. (1999). Functions of the MDM2 oncoprotein. Cell. Mol. Life Sci. 55, 96-107. (Pubitemid 29077858)
9. Fridman, J.S., and Lowe, S.W. (2003). Control of apoptosis by p53. Oncogene 22, 9030-9040. (Pubitemid 38121703)
10. Grand, R.J., Owen, D., Rookes, S.M., and Gallimore, P.H. (1996). Control of p53 expression by adenovirus 12 early region 1A and early region 1B 54K proteins. Virology 218, 23-34. (Pubitemid 26133083)
11. Guse, K., and Hemminki, A. (2009). Cancer gene therapy with oncolytic adenoviruses. J. B.U.ON. 14(Suppl. 1), S7-S15.
12. Huang, J.H., Zhang, S.N., Choi, K.J., et al. (2010). Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol. Ther. 18, 264-274.
13. Kim, E., Kim, J.H., Shin, H.Y., et al. (2003). Ad-mTERT-D19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum. Gene Ther. 14, 1415-1428. (Pubitemid 37268220)
14. Kim, J., Cho, J.Y., Kim, J.H., et al. (2002). Evaluation of E1B geneattenuated replicating adenoviruses for cancer gene therapy. Cancer Gene Ther. 9, 725-736. (Pubitemid 34971303)
15. Kim, J., Kim, J.H., Choi, K.J., et al. (2007). E1A-and E1B-double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. Hum. Gene Ther. 18, 773-786. (Pubitemid 47502844)
16. Kubbutat, M.H., Ludwig, R.L., Ashcroft, M., and Vousden, K.H. (1998). Regulation of Mdm2-directed degradation by the C terminus of p53. Mol. Cell. Biol. 18, 5690-5698. (Pubitemid 28450520)
17. Kwon, O.J., Kim, P.H., Huyn, S., et al. (2010). A hypoxia-and afetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas. Clin. Cancer Res. 16, 6071-6082.
18. Lee, Y.S., Kim, J.H., Choi, K.J., et al. (2006). Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin. Cancer Res. 12, 5859-5868.
19. Lin, J., Chen, J., Elenbaas, B., and Levine, A.J. (1994). Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8, 1235-1246. (Pubitemid 24163450)
20. Lin, J., Jin, X., Page, C., et al. (2000). A modified p53 overcomes mdm2-mediated oncogenic transformation: A potential cancer therapeutic agent. Cancer Res. 60, 5895-5901.
21. McKinney, K., and Prives, C. (2002). Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol. Cell. Biol. 22, 6797-6808.
22. Michael, D., and Oren, M. (2003). The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol. 13, 49-58. (Pubitemid 36269180)
23. Miyashita, T., and Reed, J.C. (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293-299.
24. Momand, J., Jung, D., Wilczynski, S., and Niland, J. (1998). The MDM2 gene amplification database. Nucleic Acids Res. 26, 3453-3459. (Pubitemid 28347214)
25. Muller, H.K., Bucana, C.D., Kripke, M.L., et al. (1994). Ultraviolet irradiation of murine skin alters cluster formation between lymph node dendritic cells and specific T lymphocytes. Cell Immunol. 157, 263-276. (Pubitemid 24259469)
26. Muller-Tiemann, B.F., Halazonetis, T.D., and Elting, J.J. (1998). Identification of an additional negative regulatory region for p53 sequence-specific DNA binding. Proc. Natl. Acad. Sci. U.S.A. 95, 6079-6084. (Pubitemid 28248967)
27. Oliner, J.D., Kinzler, K.W., Meltzer, P.S., et al. (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358, 80-83.
28. Olivier, M., Eeles, R., Hollstein, M., et al. (2002). The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19, 607-614. (Pubitemid 34556481)
29. Onel, K., and Cordon-Cardo, C. (2004). MDM2 and prognosis. Mol. Cancer Res. 2, 1-8. (Pubitemid 38167102)
30. Prives, C., and Hall, P.A. (1999). The p53 pathway. J. Pathol. 187, 112-126. (Pubitemid 29009841)
31. Querido, E., Marcellus, R.C., Lai, A., et al. (1997). Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells. J. Virol. 71, 3788-3798. (Pubitemid 27172392)
32. Sauthoff, H., Pipiya, T., Chen, S., et al. (2006). Modification of the p53 transgene of a replication-competent adenovirus prevents mdm2-and E1b-55kD-mediated degradation of p53. Cancer Gene Ther. 13, 686-695. (Pubitemid 44264472)
33. Selivanova, G., and Wiman, K.G. (2007). Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 26, 2243-2254. (Pubitemid 46536645)
34. Tang, H.J., Qian, D., Sondak, V.K., et al. (2004). A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin. Br. J. Cancer 90, 1285-1292. (Pubitemid 38496826)
35. Vazquez, A., Bond, E.E., Levine, A.J., and Bond, G.L. (2008). The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 7, 979-987.
36. Vecil, G.G., and Lang, F.F. (2003). Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J. Neurooncol. 65, 237-246. (Pubitemid 37526816)
37. Vogelstein, B., and Kinzler, K.W. (1992). p53 function and dysfunction. Cell 70, 523-526.
38. Vogelstein, B., Lane, D., and Levine, A.J. (2000). Surfing the p53 network. Nature 408, 307-310.
39. Wu, Q., Moyana, T., and Xiang, J. (2001). Cancer gene therapy by adenovirus-mediated gene transfer. Curr. Gene Ther. 1, 101-122.
40. Wu, X., Bayle, J.H., Olson, D., and Levine, A.J. (1993). The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7, 1126-1132. (Pubitemid 23207405)
41. Yang, C.T., Song, J., Bu, X., et al. (2003). Herpes simplex virus type-1 infection upregulates cellular promoters and telomerase activity in both tumor and nontumor human cells. Gene Ther. 10, 1494-1502. (Pubitemid 36992161)
42. Yin, C., Knudson, C.M., Korsmeyer, S.J., and Van Dyke, T. (1997). Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385, 637-640. (Pubitemid 27087577)
43. Yoon, A.R., Kim, J.H., Lee, Y.S., et al. (2006). Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin. Hum. Gene Ther. 17, 379-390.
44. Yun, C.O. (2008). Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy. Curr. Opin. Mol. Ther. 10, 356-361.
45. Yun, C.O., Kim, E., Koo, T., et al. (2005). ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis. Cancer Gene Ther. 12, 61-71. (Pubitemid 39665244)